Business
Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox Vaccines
Exercised options total USD 97 million, covering manufacturing of bulk vaccine and supply of freeze-dried vaccines.Company upgrades full-year financial guidance COPENHAGEN, Denmark, May 11, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Center for the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), has exercised additional options v
About this update from Bavarian Nordic A/s
[{"type":"image","alt":"Bavarian Nordic A/S","displaySize":"","headline":null,"caption":"Bavarian Nordic A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":224,"height":118,"url":"https://media.zenfs.com/en/globenewswire.com/8b66f55ff95ddf48491741d682cbdfa0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Vt7ueaWHpEtJLQshsI7uOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMQ--/https://media.zenfs.com/en/globenewswire.com/8b66f55ff95ddf48491741d682cbdfa0","width":224,"height":118},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/Vt7ueaWHpEtJLQshsI7uOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMQ--/https://media.zenfs.com/en/globenewswire.com/8b66f55ff95ddf48491741d682cbdfa0","width":224,"height":118}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Exercised options total USD 97 million, covering manufacturing of bulk vaccine and supply of freeze-dried vaccines.","length":115,"tagName":"p"}]},{"val":[{"type":"text","content":"Company upgrades full-year financial guidance","length":45,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":160,"olType":false},{"type":"text","content":"COPENHAGEN, Denmark, May 11, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Center for the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), has exercised additional options valued at USD 97 million under the existing contract to supply a freeze-dried formulation of JYNNEOS® smallpox vaccine.","length":457,"tagName":"p"},{"type":"text","content":"The options will support the manufacturing and supply of freeze-dried JYNNEOS, including manufacturing of additional bulk vaccine necessary for fulfilling the contract, as well as supplemental payments, triggered by the demonstration of an extended shelf-life.","length":260,"tagName":"p"},{"type":"text","content":"These options secure the remaining doses under the original order for 11.5 million doses, and the freeze-dried doses will be manufactured and delivered during 2027. The order for bulk vaccine, which represents the majority of the contract value, is to replace the bulk consumed for liquid-frozen doses supplied to BARDA during the monkeypox outbreak in 2022/23. The vaccine bulk will be invoiced during 2026, and c...